CD4 and melanoma: Importantly, recipients of H2-Aacit/cit BM (mixed 1:1 with CD45.1 WT BM) could still strongly inhibit B16F10 melanoma (Fig. 5 E), while they had similar numbers of splenic B cells and both CD4 and CD8 T cells as WT BM recipients (Fig. S4 C).